StockData

Bolt Biotherapeutics vs HCW Biologics

BOLT and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BOLT and HCWB compare

Bolt Biotherapeutics is the larger company, worth 7.6 times as much as HCW Biologics ($10.9M against $1.4M).

HCW Biologics grew revenue faster over the last twelve months (700% versus −51.3% for Bolt Biotherapeutics).

HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −1034% at Bolt Biotherapeutics.

Bolt Biotherapeutics scores higher on the StockData Score (8 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBOLTHCWB
Size and price
Market cap$10.9M$1.4M
Share price$5.65$0.777
Change, 1 year23.6%−95.7%
Change, 5 years−96.9%−99.9%
Beta (5Y)0.132.48
Employees23–
StockData Score
Total score8 (better)6
Valuation score13 (better)
Growth score12 (better)
Performance score11
Health score5 (better)0
Dividend score00
Valuation
P/S4.3×0.2× (better)
P/B1.3×0.2× (better)
Fair value$5.40$15.10
Margin of safety−4.6%94.9% (better)
Growth
Revenue growth (TTM)−51.3%700% (better)
Revenue growth, 5Y average102% (better)−57.9%
Profitability
Gross margin–96.7%
Operating margin−1098%−115% (better)
Net margin−1034%−83.8% (better)
Return on equity−129% (better)−151%
Return on invested capital–−70.7%
Financial health
Debt / equity0.000.88 (better)
Interest coverage–−14.0×
Current ratio2.05 (better)0.06
Altman Z-score−20.86−7.21 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−0.28%–
Shareholder yield−0.28%0.00% (better)
Ownership
Held by institutions31.0%5.6%
Held by insiders12.2%34.9%
Insider net buying, 12 months$196K$532K (better)
Short interest, % of float2.8%4.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.